Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. This press release and further information about PDL BioPharma, Inc. can be found at www.pdl.com.

Forward-looking Statements

This press release contains forward-looking statements, including regarding PDL's expectations with respect to its 2009 royalty revenues, expenses, net income and cash provided by operating activities.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

    --  The expected rate of growth in royalty-bearing product sales by PDL's
        existing licensees;
    --  The relative mix of royalty-bearing products manufactured and sold
        outside the U.S. versus manufactured or sold in the U.S.;
    --  The ability of our licensees to receive regulatory approvals to
        market and launch new
        royalty-bearing products and whether such products, if launched, will
        be commercially successful;
    --  Changes in any of the other assumptions on which PDL's projected
        royalty revenues are based;
    --  The outcome of pending litigation or disputes; and
    --  The failure of licensees to comply with existing license agreements,
        including any failure to pay royalties due.


Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014   ...   Elsevier , a world-leading provider of ... to announce the launch of the latest title in the ... Opinion in Food Science . ... with a new platform to keep up-to-date with the expanding ...
(Date:11/24/2014)... Billerica, Massachusetts (PRWEB) November 24, 2014 ... Simplify Panels ” from METTLER TOLEDO demonstrates how ... panel. , Power analytics and sample panel design ... control cycle chemistry and protect against corrosion and ... take up a significant amount of panel space. ...
(Date:11/22/2014)... November 21, 2014 During his lifetime ... the need to surround himself with great people and ... entrepreneur, his friends often marveled at his extraordinarily courageous ... his life and -- even with his death impending—that’s ... Alzheimer’s disease that would ultimately take his life. , ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market ... (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... to 2018” analyses and studies the major market ... Europe, Asia, and Rest of the World. , ... spread through 135 pages and in-depth TOC on ...
Breaking Biology Technology:Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... , ... therapeutics company, announces that the first clinical center in the,US, ... the phase III clinical study of Alpharadin in men with,castration-resistant ... the skeleton. , The ALSYMPCA (ALpharadin ...
... Dec. 11 Gwathmey, Inc., a pre-clinical contract ... aureus, and cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... with small businesses and the federal government. Prior ...
... ... announces the opening of a NEW 2nd North American facility in Marietta, OH. The facility ... the North American market, specifically in the area of New Product Introductions (NPI) for temperature-controlled ... Hatboro, PA ...
Cached Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... published research study examining only marketing directed at ... food restaurants has found that the majority of ... to such marketing tactics. , Authored by Arizona ... the study is the first to examine the ... exterior of fast food restaurants and its relationship ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... helped make genome sequencing much more common than in the ... different sequencing methods and the best ways to evaluate these ... measure the validity of genome sequencing. The method, which ... for the evaluation of a wide range of genome sequencing ...
... fish from Lake Victoria are described by ... and the Institute of Biology Leiden (Section Integrative ... in honour of Tijs Goldschmidt , author of ... the dramatic extinction of hundreds of cichlid species in Lake ...
... temperatures below freezing with antifreeze proteins. How the larva ... withstand temperatures down to -30 degrees Celsius is reported ... Dr. Martina Havenith from the Department of Physical Chemistry ... . Together with American colleagues, the RUB-researchers showed that ...
Cached Biology News:Researchers develop tool to evaluate genome sequencing method 2A new fish species from Lake Victoria named in honor of the author of Darwin's Dreampond 2Dance of water molecules turns fire-colored beetles into antifreeze artists 2
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
...
... Adapted to Sf-900 ... were isolated from Spodoptera ... insect cells (1). The ... to serum-free suspension culture ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: